Back to mobile site

More on SYRE

- Summary
- Chart
- Profile
- Historical

Data

- Earnings (-420.0% Growth)
- Ratings (9.4 Score)

Upcoming Events

- Earnings (11/5/26)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

Spyre Therapeutics (NQ:SYRE)
Delayed: 94.68 +3.28 (3.59%)
Prev. Close $91.40  
Open$92.78 
52 Wk High$ 
52 Wk Low$ 
Day High$95.17 
Day Low$92.32 
P/E N/A  
EPS$ 
Volume239,596 

Friends, Peers and Foes (?): ABVX, ORKA, INTU, NCNO, SMTC (more...)

Oct 18, 2026 09:30 AM Spyre Therapeutics presents IBD antibody data at UEGW 2026
Oct 18, 2026 09:30 AM Spyre Therapeutics Announces Clinical and Preclinical Data Presentations at United European Gastroenterology Week (UEGW) 2026
Oct 12, 2026 02:17 AM UBS Starts Spyre (SYRE) at Buy
Oct 9, 2026 05:01 PM Form SCHEDULE 13D/A Spyre Therapeutics, Inc. Filed by: Fairmount Funds Management LLC
Oct 9, 2026 10:05 AM Jefferies reiterates Top Pick on Spyre
Oct 7, 2026 08:00 AM Form 8-K Spyre Therapeutics, Inc. For: Oct 05
Oct 6, 2026 04:42 PM Form 424B5 Spyre Therapeutics, Inc.
Oct 5, 2026 08:14 PM Spyre Therapeutics prices $350M stock offering at $85 per share
Oct 5, 2026 08:13 PM Spyre Therapeutics Announces Pricing of $350.0 Million Public Offering of Common Stock
Oct 5, 2026 04:31 PM Spyre Therapeutics stock falls on public offering launch
View All Articles

Entities mentioned with SYRE

View All Entities